While many women experience physical symptoms prior to the onset of their period or premenstrual syndrome (PMS), a smaller subset of women suffer from Premenstrual Dysphoric Disorder (PMDD), a more severe form of premenstrual [...]
There is excellent data to support the use of selective serotonin and serotonin- norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to [...]
There is excellent data to support the use of selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to take [...]
Sepranolone is a neuroseroid now in Phase II clinical trials for the treatment of premenstrual dysphoric disorder (PMDD).
When we meet with women reporting premenstrual symptoms, we often recommend that they avoid the use of alcohol. Analyzing 19 previously published studies of alcohol and PMS, researcher found that risk for PMS risk [...]
PMDD or premenstrual dysphoric disorder has always been a bit of mystery. We explain that PMDD is triggered by changes in reproductive hormone levels, but when you look at hormone levels in women with PMDD, [...]
Multiple studies support the efficacy of serotonin reuptake inhibitors (SRIs) for the treatment of premenstrual dysphoric disorder (PMDD). In the initial studies, treatment was administered daily throughout the entire menstrual cycle. Researchers observed that for [...]
For women with premenstrual dysphoric disorder (PMDD), selective serotonin reuptake inhibitors (SSRIs) are the first line of pharmacological treatment. A significant body of evidence, including numerous double-blind, randomized studies, supports the effectiveness of SSRIs in [...]
About 75% of women with regular menstrual cycles report unpleasant physical or psychological symptoms premenstrually. For the majority of women, these symptoms are mild and tolerable. However, some women have more severe and disabling symptoms, or premenstrual dysphoric disorder (PMDD). Several years ago, a large, multicenter trial of calcium supplementation found that calcium (600 mg twice a day) significantly reduced both the physical and emotional symptoms of PMS; however, it has not been clear whether calcium supplementation might be effective for more severe premenstrual symptoms or PMDD.
The American Psychiatric Association is now considering the possibility of including premenstrual dysphoric disorder (PMDD) in the DSM-V as a new category, rather than listing a set of criteria for PMDD in the appendix (as in DSM-IV). The diagnostic criteria remain relatively unchanged. Many feel that the Inclusion of PMDD as a distinct diagnostic category will lead to greater legitimacy for the disorder and will encourage the growth of evidence-based research in this area.
